GlassScriptPhysician profile
Corretta D Barnes
NPI 1568071504
$1,085.10
in general payments reported to CMS, 2019-2025
13 companies · $573 in 2025
The $573 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $81.37 · 2024: $431 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $292.85 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $175.48 | 2024-2025 | Wegovy, Ozempic |
| Pfizer INC. | $145.65 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.44 | 2023-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $76.28 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Corcept Therapeutics | $67.53 | 2025 | Korlym |
| Lilly USA, LLC | $59.68 | 2023-2024 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $50.13 | 2024-2025 | Voquezna |
| Amgen INC. | $49.82 | 2025 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $30.22 | 2024 | |
| Verona Pharma, INC. | $23.36 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $16.53 | 2023 | Xarelto |
| Aimmune Therapeutics, INC. | $16.13 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corretta Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.